right now, if nothing else changes, the amount of remdesivir available will sort of run out by the end of this month. so there's all these conversations that are ongoing right now, do you need more raw material to make more remdesivir? how do we amp up production in some ways. those conversations are happening. what you're hearing from gilead is by the fall, they should be in a significantly better position, but alisyn, this is a good time to remind people as much as we focused on, you know, medications like remdesivir and hydroxychloroquine and talking about a couple of vaccines, there's 160 or so vaccine candidates out there, roughly a dozen that are in human clinical trials and as far as therapeutics, medicines go, there's over 230 or so that are now in some sort of clinical trial, so there's all sorts of candidates out there that they ha have, we have been keeping an eye on. some gain steam and have impact, the antibody therapy looking at antibodies from people who have recovered and seeing if you could use those to help treat or prevent disease in others, so we're keeping an eye,

remdesivir. anti-viral drug, remdesivir. i feel good about it. it's just a feeling, you know, smart guy. they say, how do you know so much about this? maybe i have a natural ability. maybe i should have done that instead of running for president. >> there were scientific briefings that seemed like a joke. president trump telling people to inject themselves with cleaning product. >> i see the disinfectant that knocks it out in a minute. one minute. is there a way we can do something like that? by injection inside. >> or taking hydroxychloroquine. >> i'm taking it. hydroxychloroquine. >> when? >> right now. yeah. couple of weeks ago. started taking it. because i think it's good. i've heard a lot of good stories and if it's not good, i'll tell you right. i'm not going to get hurt by it. >> belarus is saying that hockey and ice and vodka are going to cure the coronavirus. >> translator: there are no viruses here. did you see any flying around? i don't see them, either. it's a refrigerator. it's not that different from saying that injecting yourself w

gilead setting the price of its coronavirus drug remdesivir this morning.guest meg? >> that is daniel o'day the ceo of gilead. dan, thanks for being here this morning. a very important moment for gilead and the drug industry as a whole. one industry publication writing this is the moment that could define the pharmaceutical industry reputation for years to come you set this price in line with what a lot of people expected. you said well below the value the drug brings but 30% higher to u.s. insurers than to government insurers around the world in developed countries tell us about how you set this price. >> yeah, thanks, meg you're right, this is a very important decision for gilead. we have given consideral thought to at the center of all that thinking whether it was how fast we put the clinical trials together and the decade-long investment in antivirals and the donation program to get patients access early and the same focus went into the price. although this medicine adds significant value to the health care system we reducing the hospital days, we decid

how much is remdesivir baked into the price? how much of the price is around remdesivir?ee demand falling because there was an effective vaccine, would that change the arithmetic? tyler: good question. , i thinkof the base most would argue gilead is worth about $70 per share, may high 60's. probably five dollars of that is remdesivir. in an optimistic scenario, depending on if you're willing to ascribe multibillion revenues , maybe if you get into the mid-80's or $90 per share. i do not think there is a ton of value in the stock from remdesivir. if a vaccine does not come along, i could argue they could both exist. a vaccine, even if it is effective but it is likely not to provide coverage for every single person. there will still be a need for an acute option. ,rom a covid-19 perspective this combination could make a lot of sense because unity the acute treatment with remdesivir and a vaccine. companies going to make any money on the drugs? are they saying we will do it at cost and make it widely available, whether it is treatment of the vaccine? will they make money or

i'm thinking of gilead's remdesivir.irill: there is enough of a problem out there for all of the treatments that work. it is not really a competition. they showed some modest improvement. our drug also helps moderate cases but we see substantial improvement in our patients. it can also be taken with tablets, versus injection with remdesivir. but again, the world needs all possible treatments. one of the problems, there was no antiviral against covid. so it's a great improvement that we have this drug that has been proven to work well. scientist taylor: --taylor: i am not a scientist, so walk me through something to make sure i understand correctly. it was used in clinics before the third stage clinical trial. case, what are you accepting from the third stage clinical trial? arill: we are working with different dosage, but to make it simple, this was a japanese drug that worked well against the flu in japan. but there was the question, covid? work well against with some modifications, we have shown that it does work well

he seems to worry with some degree remdesivir, it is more effective and used in people who are moderatelyll, not seriously ill or just literally on the way out. i don't want to see hydroxychloroquine only used in the environment, some of the stories or reports that come back to me from doctors in texas is that it seems to be of most value used as an outpatient, someone who has tested positive, beginning to show symptoms and as a rescue in that setting and of course the advantage of hydroxychloroquine over remdesivir is it can be administereda orally in remdesivir has been required iv access, so there is the availability of the treatment entirely as an outpatient basis and that is intriguing and certainly something that is going to be necessary in the fight against disease. i know there are a number of studies going on right now, i want the studies to be done and i want people to have the data and i want them to have accurate data in front of them, right now wete seem to be working with people who have delivered bundles of antidotal residence which is intriguing but it doesn't prove the po

remdesivir we found out today that the pricing going forward for roughly a five-day trial $2,300 fornment-backed programs. $3,100 on the commercial market place. does president trump approve of that pricing considering there's criticism whether that's too high? >> that's a really good, important and substantive question i think deserves a good answer to and first the wholesale acquisitions costs or the federal supply schedule about 3,200 for a course of remdesivir and remdesivir is an in-patient drug done by infusion and because it is an in-patient drug the patient would be very unlikely to see the cost of the drug and to pay the cost of the drug because the way that hospitals get reimbursed for in-patient drugs is paid flat fees for admission and as explained to me this means in layman's terms that hospitals have to eat the cost of treatment used and buying it for say $3,200 the wholesale acquisition cost and that remdesivir drug saves that patient time in the hospital they only spend a third of the time in the hospital as a patient without it that would mean that the hospitals are

. >> let's talk about remdesivir.hat is the current data and thinking in the medical community about whether it's an effective treatment and whether we have enough of it? >> yes, so remdesivir people may remember is this medication it was an existing medication, so it was brought off the shelf to see if it would work against this new coronavirus and the answer was, yes, it did seem to have some impact. it shortened hospitalization from 15 days to 11 days, about 30%. it was pretty significant in terms of that impact. it wasn't clear that it actually saved lives, that it decreased mortality but it was the only thing that seemed to work and had emergency use authorization. right now, if nothing else changes, the amount of remdesivir available will sort of run out by the end of this month. so there's all these conversations that are ongoing right now, do you need more raw material to make more remdesivir? how do we amp up production in some ways. those conversations are happening. what you're hearing from gilead is by the

remdesivir is going to require iv access. there's the availability of the treatment done entirely as on outpatient basis, and that's intriguing. that is certainly something that is going to be necessary in the fight against this disease, so look, i know there are a number of studies going on right now. i want those studies to be done. i want people to have the data. i want them to have accurate data in front of them. right now, we seem to be working with people who have delivered bundles of anecdotal evidence, which is intriguing, but it doesn't prove the point. the studies are under way, and i think there's been significant effort to try to get those studies done quickly, and that's going to be an important part of this. >> representative, we saw house democrats unveil their proposals for a police reform bill. is there anything on its face that you can sign onto? >> well, again, and similar to the last bill to the coronavirus, here's something that's constructed behind closed doors, only input from their side of the dais, an

researchers say treating patients with remdesivir early is key in their progress.and kumasi. >> thank you, jobina. >>> now checking with mike for a look at the forecast. good morning, mike. >> good morning, reggie, kumasi. hi, everyboy. welcome back if you're joining us. it's june 1 and a little gray out there. accuweather highlights brighter and warmer as temperatures rebound from that cool, wet weekend. seasonal tonight with fog near the coast and our coolest weather will be this weekend with another chance of showers saturday and possibly sunday also. let's talk about today and you can see the fog retreating back to the coast except for right around the golden gate bridge and heading over to places like richmond and emeryville and even that kind of goes away as we head into the afternoon hours. so, let's talk about your temperatures and down in the south bay, 76 in milpitas and 78 san jose and santa clara and los gatos and as you head up from palo alto to redwood city and mid 50s along the peninsula coast to few upper 60s in downtown and south san francisco and

people in michigan nearly 90 cases linked to a single bar and the high cost of that promising drug remdesivir, even if you have insurance >>> the four officers charged after the death of george floyd in court trial date now set and the warning the judge gave to both sides >>> the new firestorm, president trump retweeting video of a couple pointing guns at protesters after promoting then deleting video of an apparent supporter shouting white power. >>> froing outrage over the bounty russian officials allegedly put on u.s. service members in afghanistan. the kremlin responding this our inter interview. the bipartisan demand, how much did president trump know >>> pleading gmt, the suspected golden state killer, while he'll avoid the death penalty. >>> the u.s. prepared for more mail-in voting, we contacted all 50 states. what we found. >>> and what the nation's pediatricians say on sending kids back to school why some parents are surprised. >> announcer: this is "nbc nightly news" with lester holt. >>> good evening, everyone, it is great to be back with you, as we start a new week tonight, despe

remdesivir in particular reduces hospital time by a third.ipped to handle the increase in cases we have seen. reporter: there's a national conversation going on right now about the proper place of symbols of the confederacy, statues, memorials, names, and the president has repeatedly inserted himself into this debate. a lot of people are trying to understand what his view of memorializing the confederacy is and proper place for the confederate flag so a couple questions. one, does he believe, does president trump believe that it was a good thing that the south lost the civil war? and two, has he understood, for example, banning the confederate flag at his own events? >> your first question is absolutely absurd. he's proud of the united states of america. second, with regard to our statues, americans oppose tearing down our statues. there's a harvard harris poll released just last week that shows 60% of respondents said that statues should remain. 71% said local governments should block groups from destroying the statues. he stands on the side

reporter: melissa, the white house says it approves of the pricing model it put forward for remdesivir. that is the drug made by gilead used in hospitals under the supervision of doctors to treat covid-19 patients. there has been some success with it. the price sheet if you want to call it that, $390 a vial for the federal government, $520 for insurance companies. over course of five-day treatment that amounts to roughly $2300 for the government, $3300 for the insurers. senator bernie sanders is among those with concerns, describing that in a tweet quote, price gouging. the white house says it is the right price point. >> if they buy remdesivir for say $3200, which is the wholesale acquisition cost and that remdesivir drugs saves that patient time in the hospital, they only spend a third of the time in the hospital as a patient without remdesivir that would mean that the hospitals are actually profiting because they're getting the patient out early. so that's, basically all cops down to saying that the patient will not see that cost. reporter: over the weekend the health and human serv

this is really attacking that problem wearers remdesivir is attacking the virus itself. from the pandemic worldwide, the numbers are likely to get rising for some time. yes. the factors everyone an individual attention span. i can usually watch tv for ten minutes before a start to wander. we have a collective attention span as a society and asa attention span as a society and as a world and i think out collective attention span has shifted, certainly in the us our attention is very focused on race relations and so that has taken away a lot of the attention from covid—i9. but, of course, the virus doesn't switch to the attention so it continues to ride in the background. looking at the big nectar, how optimistic are you? there are a couple of reasons they are very optimistic, there area they are very optimistic, there are a couple of reasons i am pessimistic. they will share all of those with you. a couple of things that are good, got dexamethasone, which imagine, and remdesivir, and nomination treatments like user with hiv where there is a cocktail medicines coming toget

that's a critically important research finding and a lot of research is happening but remdesivir today if i was going to be admitted to the hospital with covid, if i have shortness of breath, if my oxygen saturation is low and i need admission to the hospital i'd like to get to remdesivir or in the study, act two in which all participants are getting remdesivir in addition to another experimental drug. >> dr. carlos del rio, always good to have you on. thanks very much. >> take care. >>> all right, as the minneapolis city council pushes and votes actually with the veto proof majority to dismantle their police department, we're learning more about the economic disparity that black people in minneapolis in the twin cities have faced for generations. we're going to have a deep look at the number with the naacp, next. look at that scuffed up wall. staring at you. embarrassing you in front of your in-laws. spreading rumors about you at work. that wall is your everest - but not any more. today let's paint. that wall never knew what hit it. today let's paint. behr. exclusively at the home dep

when we heard about remdesivir, we have heard a lot about hydroxychloroquine. nhaeaotrd does it come as a surprise? >> no, the study was set up in march. 5 17tysh htaosls invol -- british hospitals involved. vesix different arms, a complex multi-armed study, including hydroxychloroquine, remdesivir, and so on. the arm with dexamethasone looks as though it has come up great. there's no doubt from the fires you've heard, there are ldnhe ventilator anom patients fo and they are put onto,s it' been along longer than i have been a doctor. it has been around 60 years, well before i starteded it is available to third world pharmacists around the world. we use it for all sorts of things in medicine. it is like $.10 a pill in parts of africa. great news. y: we have all been waiting for a breakthrough. while, researchers li yourself have said the remedy could -- the therapy could come quicker than the vaccine. is this the breakthrough weere waiting for? >> no, this is supportive. this is to support people who have covid bed. -- bad. you don't get admitted y to a donit't

there could be a change in perception of the therapy remdesivir.nly a limb -- only a limited benefit in a large trial. barclays, about 700 workers will begin returning to their offices in the u.k., the u.s., and in india next month. and of them are traders others who cannot work from home. barclays says the rest of its employees will still work at home until at least the end of september. in new york city, the finance industry may not recover from the coronavirus for six years according to a new study from the software firm think iq. the new york area has lost about 8% of its finance jobs this year alone. that is your business flash update. we are going to go from our business flash to the bloomberg first word news. president trump today urged states to crackdown on protests in the aftermath of the death of a black man at the hands of police in minneapolis. audio of news obtained the president's conference with governors and law enforcement. pres. trump: you have to dominate. if you don't dominate, you will be wasting your time. they will run over

we have identified two very promising pharmaceutical treatments, remdesivir and dexamethasone. as of today, we have allocated more than 120,000 courses of remdesivir to all of the 50 states. we have added dexamethasone, very low cost steroid, to our treatment guidelines, and we believe it is reasonable to assume that other corticosteroids which may be more readily accessible in some places would have similar immunological effects. another promising therapeutic, convalescent plasma, has been used to treat more than 25,000 americans in nearly 3,000 sites across country pair there are no certainties come up with 140 clinical trials underway in thea pretty safe bet that more good news on therapeutics on the way and on the way soon. finally, we've announced large investments to support three different vaccine candidates all the way through to manufacturing. these candidates are now in human clinical trials, some with the potential to start delivering safe and effective doses before the end of the year, and we will be adding support for several more candidates. we are expanding manuf

clearly, we do have remdesivir. we have evidence that steroids can improve therapy.you mentioned, we have c convolesent plasma, using the antibodies from individuals that have gotten better from covid, that are currently under evaluation. >> since i have a moment, i'll go to dr. hahn and have him answer the question, too. >> remdesivir has been authorized based on hospitalization days reduction. steroids were mentioned. plas plasma, we've evaluated the safety through a large, extended program through the mayo clinic, and it is found to be safe in over 20,000 patients who administered it. we're waiting for the safety data, and we'll be passing it along to barda, the sponsor of the program. i think the data will help us in the development of the antibodies. we have a number of sponsors who have come in from antibody studies. we're already well into that treatment. monoclonal antibodies are synthetic antibodies that will provide protection against the virus. we're hopeful those studies by late summer/early fall will provide us information about the effectiveness and saf

as i mentioned remdesivir has been authorized based on its reduction in hospitalization days. the steroids were mentioned. convalescent plasma we've evaluated safety through a large expanded access program at the mayo kline an it's been found to be safe and over 20,000 patients have been administered it. we're waiting for the safety data, and we'll be passing the data along to the sponsor of that program. i think that antibody data will help us in terms of the development of monoclonal antibodies. we've had a number of sponsors coming in for monoclonal antibody studies. monoclonal antibodies are synthetic antibodies that will provide -- the theory is they will provide protection against the infection of the virus, and we're hopeful that those studies by the late summer, early fall, will provide us information about their effectiveness and safety. >> so you're optimistic that there will be more than one treatment available this fall for teachers, administrators, older adults? >> yes, sir, i'm optimistic. >> thank you very much. senator murray. >> thank you very much to all of o

and that's what's happening with remdesivir right now. in the case of hydroxychloroquine, for example, they released a bunch to florida and it's kind of sitting in the florida public health group and people don't know what to do does, it allows the government to release things kind of in donations and stockpiles, like kind of an emergency, it doesn't really fit in from a medical perspective. >> that makes sense. a lot of vacc >> overall, i'm kind of optimistic. the vaccine work is going much faster than people think. but on the other hand, it's not going to be tomorrow. it's probably not even going to be january 2021, but probably in the spring, we will probably have enough of the most promising one to treat a group of patients with or a group of people in public with. of course, some of the front runners are being funded by the u.s. government, operation warp speed and i think they've designated five people or five groups that they have the most promise and some of them include a group from oxford, a group from boston, that's there's a c

saying hydroxychloroquine could weaken the effectiveness of remdesivir joining us now dr.tlieb, cnbc contributor, he serves on the board of illumina and pfizer let's talk about the fda action against hydroxychloroquine >> they pulled the emergency use authorization which granted the use of the drug in hospital setting and collecting the information at the same time that drug was being used in those circumstances. mind you, this is a drug not available on the market but by pulling the emergency use authorization, it was acknowledged it no longer meets the statutory burden there has been a number of studies now that have come out and haven't shown a benefit. a number of random studies under way. the fda might have gotten a look at the data and turned their hands. as well as the decision that it could interfere. it does work against coronavirus. the fact that it could interfere with the drug that has been otherwise effective, that could have tipped the agency's hand. >> how dangerous could it be or is this something we don't think is effective and the down side is that it cou

meanwhile, of course, we did get that highly anticipated news on the price of remdesivir this morning from gilead. more than $3,000 in the united states for a course of treatment from commercial insurers and less for government insureerhri the world and around the united states paying 30% more. we talked with gilead's ceo this morning on how they set the price. here's what he said. >> we priced it at the value, excuse me, at the price that allows for access across the developed world. and what we've done is we have one price for all governments across the development world based upon the lowest purchasing power of the lowest developmented countries and provided that price to all governments around the world that's important, i think. it's our responsibility and we feel it is the right thing to do >> so, guys, even though the gilead price coming in below the value it creates in terms on cutting down on hospitalizations times you see gilead stock up 2.7% as wall street thinks they outlined a good rationale for this and see a lot of volume coming from this drug. carl >> all right, meg, w

you use the blood of patients who have recovered from covid-19, and you've got the gilead drug remdesiviroke with the ceo there, dan o'day, for my barron's street wise podcast this past week, and he says they're looking at ways to expand the usefulness of that drug. let's listen to a clip. >> doing formulation work to see if we can, instead of this being given as an intravenous injection which it is today, we believe we may be able to provide this inhaled version which would be less invasive, of course. >> keep in mind we've only been talking about drugs that companies already had before the pandemic that they've repurposed. we saw the first drug that was specifically made for covid-199 go into trials this month -- 19. that's from regeneral ron. we should hear results in september. so the point is there are more and better treatment options becoming available. jack: and this is so important because we've seen now even while new york is getting better, a lot of other states' cases are spiking, so we've got to make some progress on the medical front. ben, i want to turn to you about tech st

remdesivir will help the patient recover faster.t would also shorten the hospital stay by several days. >>> it is 5:47. new research suggests americans work from home full-time because of the pandemic. hardly any at-home workers have gone back to their normal place of business. ktvu's reporter shows us how the workforce may look a whole lot different, even after the pandemic. >> reporter: with the pandemic not slowing down, remote work is becoming increasingly a permanent part of the landscape. >> is a blessing in disguise. it allows a lot of people to stay away from the dangers of the pandemic. >> i love working from home. i would say i would not like it if i did not have the option to get out of the house and stretch my legs. >> reporter: according to the stanford institute for economic policy research, 42% of the u.s. labor force is working full-time from home. a little more than half that, 26%, working out their businesses, mostly essential services. a yahoo finance poll found 40% of those surveys are working at home 1% of the t

but sticking with treatments, gilead with remdesivir drug and early excitement we had said it was focusedy sick patients and now we have the results i believe from a study of people more moderately sick and what did we find from that >> exactly so that's the differentiation. when's new in these data today the data so far severe patients with covid-19 or in the nih trial a mixture of patients and this was the moderate patients, hospitalized with pneumonia and did not require oxygen supplementation and a five-day course of remdesivir gave them 65% more likelihood of having clinical improvement after 11 days versus the standard of care now they also tested the ten-day course of remdesivir and while it trended toward positivity was not significant. so kind of mixed result that is just line up with what we've seen appears to have an affect and appears to be modest, kelly. >> thank you very much >>> coming up, spacex's launch over the weekend was successful. got two astronauts to the international space station. what the historic launch means for american scepa and commercial space travel. we'l

the same story got told with remdesivir. it is used in people who are , not seriously ill or on the way out. i don't want to see hydroxychloroquine only used in that environment. some of the reports that came back to me from doctors in texas is that it seems to be of most value used as an outpatient. someone who has tested positive, beginning to show symptoms. as a rescue in that setting. the advantage hydroxychloroquine has over remdesivir's it could be distributed in a pill. remdesivir requires the access. there is the availability of treatment done entirely done. that is intriguing. that is something that will be necessary in the fight against this disease. there are number of studies going on right now. i want those studies to be done. --ant them to have asked her accurate data. we want them to be working with .eople the studies have been underway. there is an effort to get those studies done quickly. that will be an important part of this. we saw house democrats unveil the proposal, is there anything you could sign onto

gilead will try using remdesivir to see how it works in combination with other therapies.w remdesivir has been shown to work with covid-19 but it is not by anyone's definition a wonder drug. what it showed in studies in the intravenous form is that it cuts down on a hospital stay by about four days. a good thing but, again, not a wonder drug. christine, laura? >> thank you. the u.k. reporting its lowest daily death toll since the pandemic began. prime minister boris johnson is expected to lift lockdowns including for pugs. when can the british public enjoy a pint? >> reporter: well, some are enjoying pints already but only if they're a take away. i'm pointing to my local pub. they were very excited about potentially a further loosening of rules. pubs could be allowed to reopen as soon as the fourth of july. that is what we expect the prime minister will announce today. not just that, but the guidance on how. how can these businesses reopen? what procedures need to be put in place. it will not be prepandemic will be reduction in the social distancing rule. currently in the

is about to test an inhaled version of the medication has potential covid-19 treatment remdesivir ishe only drug right now that has emergency use fda approval to treat covid-19 infections. the medication is currently administered through daily ivy infusions at the hospital but gilley and sciences announced today that the fda has given the company the green light to start trials of an inhaled version of remdesivir galea de chairman and ceo says that they will screen healthy volunteers for phase, one trials this week. and they hope to begin studies in patients with covid-19 in august. next up a big bear is spotted roaming around this los angeles neighborhood, how wildlife experts moved >>where he's living tonight plus a big announcement today concerning a major golf championship. that's actually coming to the bay area will fans be they're also the mess with major league baseball and the coronavirus and will the warriors lose one of >>time now for school. >>welcome back i have some bad news for bay area golf fans who are looking forward to attending the area's first major golf tournamen

we have seen remdesivir, we may have seen dexamethasone.l reports coming out in the next few weeks of some others. i think we will start to see signs of a treatment that works. it's important to understand when a treatment that works means. it's not a magic pill that takes you from sick to healthy overnight. it's a drug that will work, will reduce the duration of hospitalization and will reduce the symptoms. it won't turn it over overnight. in terms of a vaccine, we are already seeing vaccines in the clinic, being tested in phase one trials for safety and tolerability. early this fall, august, september perhaps, we will start seeing enrollment in vaccine trials but to show efficacy with the primary end point being it reduces the onset of infections, that's going to take months and months. some people have predicted it can be done in a year. i'm a little skeptical of that. i think it will take longer than that. before we have a vaccine which is proven to be effective, best case scenario, a year to 18 months. liz: andrew, we can only hope tha

cheryl: we heard about gilead and remdesivir and they announced the price of it now, more than $3,000. i wanted to ask you if you think that price, a, is fair and b, is remdesivir the only hope we have right now to treat those that are severely ill? >> it's one of the earliest hopes. there's remdesivir, there's steroids, looks like it's being somewhat effective, then there's convalescent patient serum. the cost of these medicines will be a problem because it's not only that you have a medicine that works but you need to make sure the whole world has access to it. doesn't really help if only certain areas of the world can afford the medicine. that's just going to propagate the disease and the problem. that said, you know, it's quite possible nations could subsidize the cost of that medicine and should consider doing that because the cost to their economy is so much greater than the cost of subsidizing effective medicine. cheryl: i know the european union officials have been talking about that. i want to move to what your company is doing. you've had success with an antibody you develop

. >> exactly raise your hand if you'd rather have the drug over the vaccine does it rival remdesivir or is it the same? >> remdesivir was given to patients who are in the hospital already, but that's because it's given by an i.v. and that's how they ran the trial but many think if you give patients remdesivir before they're really ill, it will help better, whereas dexmethasone helps people when the virus is attacking the lungs while they're in the hospital. >> meg tirrell, we appreciate it >>> citigroup going to a target of $400 on the stock they walk through the five reasons you should own it right now. >>> home buying is jumping in the surge as confidence builds we'll have more when "the chgecoins. flexshares may look simple on the outside. but inside every etf... there are untold hours of careful construction... infinite "what ifs?" and contingency plans. creating funds that help target gaps in client portfolios. tap untapped potential. and strengthen confidence in you. flexshares. powered by over a century of investment expertise before investing consider the fund's investment ob

the remdesivir is a big advance, but we've run out of remdesivir in the state of alabama. the distribution of the drug has been problematic and it's also just not in great supply. so you mentioned that we had 800 new cases yesterday, our hospitals are full, particularly in montgomery. the icus there are really full and we don't have the only drug that we think can help people who are in the most dire situation. >> that is not a promising note to end on but we really appreciate you, doctor, and thanks always dpourmg coming on good information for us. >> thank you. >>> coronavirus is surging across latin america. they account for more than a third of new infections in the world. cnn has reporters around the world covering all the latest for you. >> i'm matt rivers in mexico city. region of latin america and the caribbean is now reporting more than 1.5 million confirmed cases of the virus for the first time since this outbreak began. around 1.3 million of those cases come from just four countries, brazil with the most by far followed up by peru, then chile, and then here in m

. >>> the antiviral drug remdesivir providing some hope when it comes to treating covid-19.he maker of the drug just announced the price tag, more than $3,100 for a five-day treatment. one consumer group called that an outrage but the drug company said the price reflects its goal of worldwide distribution. your thoughts on that price? >> there's a couple of things to think about. number one, the drug is costing more in the united states under private insurers than it is in developed countries, so why the discrepancy and, number two, the pricing is based on the fact that previous research suggested that remdesivir treatment could reduce hospitalization stay, so you could get somebody out of the hospital faster, which would theoretically save the hospital a lot of money, but we have to see if that works out in a large scale. >> when it comes to protection what is the difference between those face shields and a regular cloth mask? >> well, they are fashionable. look, i have one right here. what's great about these right here is they're comfortable. they actually -- your mouth i

remdesivir has been on the market for so long.itially studied to treat hepatitis c and then ebola. the way this antiviral drug works it works in a basic mechanism where it can attack all viruses not specifically one virus so that's why i think that it's easier for researchers to look at a drug that's already on the market and say listen, how could this potentially work against covid-19? and remdesivir is showing some promise. >> okay. when we talk about the virus there's some new information from researchers in florida this morning who say that covid has mutated and it's mutated in a way that makes the virus more infectious. the mutation gives the virus more spikes and those spikes are more stable for the virus therefore making it easier to get into the cells of people. we're hearing this after the w.h.o. just last week said mutations did not make it more easily transmissible. so how legitimate, in your opinion, is the florida research and if it's true what does that mean? >> yeah. a new observation if you will by a few scientists

gilead, the maker of remdesivir, has said that a course of remdesivir treatment which is about six vials0. in comparison to let's say a course of some chemotherapy, it could be $16,000. cost is always an issue but, again, gilead saying this drug priced under value, that the pricing of a course of treatment will provide access to any and all patients who need it and they mentioned yesterday that by the end of 2020 they will have committed $1 billion in terms of development and manufacturing of remdesivir, so high costs involved for sure. >> that's for sure. besides drugs, what are doctors learning about how to treat patients with coronavirus? >> they're learning a lot. critical care specialists, pulmonologists are really learning new treatments, one of them, that proning positioning of turning patients over so that they can get better oxygenation in their blood, delaying intubation as long as possible, and every single day they're learning about this virus. >> yeah, and that's so important because you said at the very beginning there was so much that we didn't know but we are starting to

there are a number of drugs, some shown here, i will get to remdesivir in a moment. there are antivirals, plasma, immune-based therapies dampening the immune response, i don't want to call them antibodies, natural products they are, directed against the virus themselves. there was a groundbreaking study a month or so ago that showed a single drug, remdesivir, and antiviral, in a trial showed significant improvement over faster time of recovery for those who were infected and in the hospital with lung disease. , a steroid, was shown in the u.k. to reduce mortality on people with ventilators and others with serious lung disease. guideline panel that is producing a document online. at nih.gov.ss that at the most recent recommendations for treatment of diseases. what about prevention? what other public health measures to protect you and protect society? it is based on social and physical distancing. we shut down the country with stay-at-home orders. we are now trying to reopen different regions of the country, that have different paces. it also takes a look at schools, t

the first is remdesivir which is an antiviral drug originally developed for ebola but it does turn out it works pretty well for this. it doesn't actually stop people from dying but what it doesn't do is it cuts the number of hospitalized days among more seriously ill people and as we can see with what is going on in texas and in florida now hospital capacity and the ability to take care of the people with this disease when they get sick is a vitally important part of the process. anything we can do to try to chop away with the number of hospital beds being used is incredibly important. the other thing that just came out in the research has finally been published was i think two days ago, they came out the study although it's fallen in prepublication review that it hasn't been officially reviewed by other physicians yet but they put out the data but it does appear good. it is a commonly used steroid and you probably had it in eyedrops in your life but we give it by vein a lot and here is the dexamethasone into groups of patients, one, people who are very sick and on ventilators and two,

120,000 courses of remdesivir to all of the 50 states. we've added dexamethasone, a low-cost steroid to our treatment guidelines, and we believe it's reasonable to assume that other cortico-steroids which may be more accessible in some places would have similar effects. another promising therapeutic, convales convalescence plasma, has been used in over 3,000 sites across the country. there is no certain see with science but with trials under way it's a safe bet that more good news is on the way and on the way soon. we've announced large investments to support three different vaccine candidates all the way through to manufacturing. these candidates are now in human clinical trials, some with the potential to start delivering safe and effective doses before the end of the year, and will be adding support for several more candidates. we're expanding manufacturing capacity and already making the vials, needles, ander is inches that we made -- syringes that we may need. our capabilities have grown exponentially in the time allowed by the patri

it may be combined with an antiviral drug that also looks good right now, remdesivir.out ventilator patients, would it be used for just serious conditions or could be used for everyone? someone who might have common symptoms and don't need to go to the hospital? who is going to take this? >> excellent question. for now it will start with patients that are just going into the hospital, not just ventilator but people on oxygen which is three quarters of all patients the go into hospital with remdesivir. then it will be looked at further with the exact question you're asking, what if i have a high risk condition, what if i get short of breat is a different one but very close cousin to prednisone. should i take the steroid when i get sick? rob: let's switch to what we have seen happen in the nursing home and care facilities across the country from this virus that has been devastating, a new milestone that is 50,000 deaths now in these nursing homes, long-term care facilities. you have seen a lot of care providers have immunity to this. a number of states, we can pull them

is at risk of running out of remdesivir by the end of the month. at the time gilyard sciences planned to ramp up their production, so we'll see how that goes. >>> in developing news, the number of confirmed cases of coronavirus is exploding at san quentin prison. it jumped to 48 cases on june 14 and then 499 cases last friday. at last check, there are 523 active cases among inmates. and inmates are telling abc 7 news that the prison is rotating guards from infected areas to uninfected areas daily. and officials are even investigating if a death row inmate has died from the virus. meanwhile, a team of uc berkeley and ucsf health experts told the "chronicle" they are worried that an outbreak inside the prison could lead to a spike in covid cases across the bay area as workers return to the community. >>> good news for new drivers. the dmv will start offering behind the wheel driving tests again today. the economy including a reopening is one of the main things we're following in our evident to build evide effort to build a better bay area. and kris r

gilead sciences has put a price on its coronavirus drug remdesivir.pany will charge the u.s. undeveloped countries more than $2200 for the typical five-day course of treatment. in may, a trial found remdesivir speeded up recovery about four days in hospitalized patients. another cell of a petrochemical business. the price is $5 billion. they call it the next step in focusing its portfolio. that is your bloomberg business flash. guy? here is what we are talking about. there is a lot of shaping put forth with b.p. today and many of the chat rooms i was looking at. the stock is reacting relatively well, but what it seems to me is that bp is selling these assets to defend the dividend. there is a nice quote if you go to the bottom of the statement that bp put out that said "proceeds from the sale would be bp for pb for general -- general corporate purposes." wonder whether that is a long-term strategy? alix: that is a good point. you want to hold oil prices come back, but you can also make an argument this is something they would be moving towards anyway